|
[1] PATTEN DA,SHETTY S. Chronic liver disease:Scavenger hunt for novel therapies[J]. Lancet,2018,391(10116):104-105.
|
|
[2] ROEB E. Matrix metalloproteinases and liver fibrosis(translational aspects)[J]. Matrix Biol,2018,68-69:463-473.
|
|
[3] XU Y,ZHOU W,JI Y,et al. Elongator promotes the migration and invasion of hepatocellular carcinoma cell by the phosphorylation of AKT[J]. Int J Biol Sci,2018,14(5):518-530.
|
|
[4] DUARTE S,BABER J,FUJII T,et al. Matrix metalloproteinases in liver injury,repair and fibrosis[J]. Matrix Biol,2015,44-46:147-156.
|
|
[5] GROSS J,LAPIERE CM. Collagenolytic activity in amphibian tissues:A tissue culture assay[J]. Proc Natl Acad Sci U S A,1962,48:1014-1022.
|
|
[6] ADHIKARI N,MUKHERJEE A,SAHA A,et al. Arylsulfonamides and selectivity of matrix metalloproteinase-2:An overview[J]. Eur J Med Chem,2017,129:72-109.
|
|
[7] KLEIN T,BISCHOFF R. Physiology and pathophysiology of matrix metalloproteases[J]. Amino Acids,2011,41(2):271-290.
|
|
[8] ARISTORENA M,GALLARDO-VARA E,VICEN M,et al.MMP-12,secreted by pro-inflammatory macrophages,targets endoglin in human macrophages and endothelial cells[J]. Int J Mol Sci,2019,20(12):3107.
|
|
[9] TOUMPANAKIS D,NOUSSIA O,SIGALA I,et al. Inspiratory resistive breathing induces MMP-9 and MMP-12 expression in the lung[J]. Am J Physiol Lung Cell Mol Physiol,2015,308(7):1683-1692.
|
|
[10] CUI N,HU M,KHALIL RA. Biochemical and biological attributes of matrix metalloproteinases[J]. Prog Mol Biol Transl Sci,2017,147:1-73.
|
|
[11] ARPINO V,BROCK M,GILL SE. The role of TIMPs in regulation of extracellular matrix proteolysis[J]. Matrix Biol,2015,44-46:247-254.
|
|
[12] AMLINEI C,CRUNTU ID,GIU爦CSE,et al. Matrix metalloproteinases involvement in pathologic conditions[J]. Rom J Morphol Embryol,2010,51(2):215-228.
|
|
[13] van DOREN SR. Matrix metalloproteinase interactions with collagen and elastin[J]. Matrix Biol,2015,44-46:224-231.
|
|
[14] DANIELE A,ABBATE I,OAKLEY C,et al. Clinical and prognostic role of matrix metalloproteinase-2,-9 and their inhibitors in breast cancer and liver diseases:A review[J]. Int J Biochem Cell Biol,2016,77(Pt A):91-101.
|
|
[15] YANG Q,LI X. Corrigendum:Molecular network basis of invasive pituitary adenoma:A review[J]. Front Endocrinol(Lausanne),2019,10:657.
|
|
[16] JIN Y,CHEN W,YANG H,et al. Scutellaria barbata D. Don inhibits migration and invasion of colorectal cancer cells via suppression of PI3K/AKT and TGF-β/Smad signaling pathways[J]. Exp Ther Med,2017,14(6):5527-5534.
|
|
[17] JING SW,WANG YD,KURODA M,et al. HIF-1αcontributes to hypoxia-induced invasion and metastasis of esophageal carcinoma via inhibiting E-cadherin and promoting MMP-2 expression[J]. Acta Med Okayama,2012,66(5):399-407.
|
|
[18] KURZEPA J,M DRO A,CZECHOWSKA G,et al. Role of MMP-2 and MMP-9 and their natural inhibitors in liver fibrosis,chronic pancreatitis and non-specific inflammatory bowel diseases[J]. Hepatobiliary Pancreat Dis Int,2014,13(6):570-579.
|
|
[19] JACOB A,JING J,LEE J,et al. Rab40b regulates trafficking of MMP2 and MMP9 during invadopodia formation and invasion of breast cancer cells[J]. J Cell Sci,2013,126(Pt 20):4647-4658.
|
|
[20] CHENG Z,LIMBU MH,WANG Z,et al. MMP-2 and 9 in chronic kidney disease[J]. Int J Mol Sci,2017,18(4):776.
|
|
[21] DONG DD,ZHOU H,LI G. ADAM15 targets MMP9 activity to promote lung cancer cell invasion[J]. Oncol Rep,2015,34(5):2451-2460.
|
|
[22] TOTH M,CHVYRKOVA I,BERNARDO MM,et al. Pro-MMP-9activation by the MT1-MMP/MMP-2 axis and MMP-3:Role of TIMP-2 and plasma membranes[J]. Biochem Biophys Res Commun,2003,308(2):386-395.
|
|
[23] ALA-AHO R,KHRI VM. Collagenases in cancer[J]. Biochimie,2005,87(3-4):273-286.
|
|
[24] IIMURO Y,NISHIO T,MORIMOTO T,et al. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat[J]. Gastroenterology,2003,124(2):445-458.
|
|
[25] NU'EZ O,FERNNDEZ-MARTNEZ A,MAJANO PL,et al.Increased intrahepatic cyclooxygenase 2,matrix metalloproteinase 2,and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection:Role of viral core and NS5A proteins[J]. Gut,2004,53(11):1665-1672.
|
|
[26] HEMMANN S,GRAF J,RODERFELD M,et al. Expression of MMPs and TIMPs in liver fibrosis-a systematic review with special emphasis on anti-fibrotic strategies[J]. J Hepatol,2007,46(5):955-975.
|
|
[27] ZHOU X,HOVELL CJ,PAWLEY S,et al. Expression of matrix metalloproteinase-2 and-14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis[J]. Liver Int,2004,24(5):492-501.
|
|
[28] GIANNANDREA M,PARKS WC. Diverse functions of matrix metalloproteinases during fibrosis[J]. Dis Model Mech,2014,7(2):193-203.
|
|
[29] WANG J,PAN W,WANG Y,et al. Enhanced efficacy of curcumin with phosphatidylserine-decorated nanoparticles in the treatment of hepatic fibrosis[J]. Drug Deliv,2018,25(1):1-11.
|
|
[30] MEIER RP,MAHOU R,MOREL P,et al. Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice[J]. J Hepatol,2015,62(3):634-641.
|
|
[31] FENG M,DING J,WANG M,et al. Kupffer-derived matrix metalloproteinase-9 contributes to liver fibrosis resolution[J].Int J Biol Sci,2018,14(9):1033-1040.
|
|
[32] EL-GINDY I,EL RAHMAN AT,EL-ALIM MA,et al. Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis in patients with HCV related chronic liver disease[J]. Egypt J Immunol,2003,10(1):27-35.
|
|
[33] LU C,RONG D,ZHANG B,et al. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma:Challenges and opportunities[J]. Mol Cancer,2019,18(1):130.
|
|
[34] LIN XL,LI K,YANG Z,et al. Dulcitol suppresses proliferation and migration of hepatocellular carcinoma via regulating SIRT1/p53 pathway[J]. Phytomedicine,2020,66:153112.
|
|
[35] HUANG CF,TENG YH,LU FJ,et al．β-mangostin suppresses human hepatocellular carcinoma cell invasion through inhibition of MMP-2 and MMP-9 expression and activating the ERK and JNK pathways[J]. Environ Toxicol,2017,32(11):2360-2370.
|
|
[36] YOSHIJI H,KURIYAMA S,NOGUCHI R,et al. Angiopoietin 2displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice[J]. Gut,2005,54(12):1768-1775.
|
|
[37] CAO LQ,SHAO ZL,LIANG HH,et al. Activation of peroxisome proliferator-activated receptor-γ(PPARγ)inhibits hepatoma cell growth via downregulation of SEPT2 expression[J]. Cancer Lett,2015,359(1):127-135.
|
|
[38] MONDAL S,ADHIKARI N,BANERJEE S,et al. Matrix metalloproteinase-9(MMP-9)and its inhibitors in cancer:A minireview[J]. Eur J Med Chem,2020,194:112260.
|
|
[39] LI JZ,LI J,LIU BZ. MicroRNA-328-3p inhibits malignant progression of hepatocellular carcinoma by regulating MMP-9 level[J]. Eur Rev Med Pharmacol Sci,2019,23(21):9331-9340.
|
|
[40] ZHANG Q,ZHANG Y,HU X,et al. Thymidine phosphorylase promotes metastasis and serves as a marker of poor prognosis in hepatocellular carcinoma[J]. Lab Invest,2017,97(8):903-912.
|
|
[41] LI T,ZHONG J,DONG X,et al. Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of theβ-catenin signaling pathway[J]. Oncol Rep,2016,35(6):3614-3622.
|
|
[42] DANIELE A,DIVELLA R,QUARANTA M,et al. Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization[J]. Clin Biochem,2014,47(3):184-190.
|
|
[43] STARR AE,DUFOUR A,MAIER J,et al. Biochemical analysis of matrix metalloproteinase activation of chemokines CCL15and CCL23 and increased glycosaminoglycan binding of CCL16[J]. J Biol Chem,2012,287(8):5848-5860.
|
|
[44] KLEIFELD O,DOUCET A,AUF DEM KELLER U,et al. Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products[J]. Nat Biotechnol,2010,28(3):281-288.
|
|
[45] YANG S,WANG L,PAN W,et al. MMP2/MMP9-mediated CD100 shedding is crucial for inducing intrahepatic anti-HBV CD8 T cell responses and HBV clearance[J]. J Hepatol,2019,71(4):685-698.
|
DownLoad: